Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

7.215 +0.335 (+4.87%)
Streaming Delayed Price Updated: 11:28 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeutix, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Ocular Therapeutix™ to Participate at Two Upcoming Investor Conferences
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Expert Ratings For Ocular Therapeutix ↗
Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst rating... 
Via Benzinga
News headline image
Ocular Therapeutix Stock Gains As Court Invalidates Drug Delivery Patent From Mati ↗
Ocular Therapeutix Inc (NASDAQ:OCUL) announce... 
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Frequency Therapeutics (NASDAQ:FREQ) stock rose 10.94% to $7.51 during Tuesday's regular session. The current volume of 277.7K shares is 160.43% of Frequency... 
Via Benzinga
News headline image
Ocular Therapeutix™ Announces Success in Patent Appeal Brought by Mati Therapeutics, Inc.
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix: Q3 Earnings Insights ↗
Ocular Therapeutix (NASDAQ:OCUL) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ Announces Update from the Centers for Medicare and Medicaid Services (CMS) for the Reimbursement of DEXTENZA®
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ to Present Data at the American Academy of Optometry Annual Meeting 2021
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 8, 2021 ↗
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •... 
Via Benzinga
News headline image
Ocular Therapeutix™ To Report Third Quarter 2021 Financial Results
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting
From Ocular Therapeutix
Via Business Wire
News headline image
What 5 Analyst Ratings Have To Say About Ocular Therapeutix ↗
Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst ratings... 
Via Benzinga
News headline image
How The Future Looks For Last Week's Biggest Losers: Vinco Ventures, Atea Pharmaceuticals And More ↗
Last week, the five biggest stock market losers declined between about 75% and 37%. Below is a look at each stock and what they may have in the cards going forward. Galera... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
Wells Fargo boosted Bank of America Corporation (NYSE:B... 
Via Benzinga
News headline image
55 Biggest Movers From Friday ↗
Gainers Phunware, Inc. (NASDAQ: PHUN) shares jumped 471.2% to close at $8.74 on Friday. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's stock is trading at a volume of 116.0 million... 
Via Benzinga
News headline image
Mid-Day Market Update: Snap Drops After Q3 Results; Creatd Shares Jump ↗
Midway through trading Friday, the Dow traded up 0.25% to 35,690.68 while the NASDAQ fell 0.46% to 15,145.78. The S&P also rose, gaining 0.02% to 4,550.53. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
35 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with Digital World Acquisition as traders circulated... 
Via Benzinga
News headline image
Here's Why Ocular Therapeutix Stock Is Sinking Today ↗
The company's experimental dry-eye treatment produced some disappointing clinical trial results. 
Via The Motley Fool
News headline image
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
10 Biggest Price Target Changes For Monday ↗
Barclays reduced the price target for The Walt Disney Company (NYSE: 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs ↗
Biotech stocks rebounded in the week ended Oct. 15, bouncing from third straight weekly losses. The strength came amid a broader market rally and some sector-specific news.... 
Via Benzinga
News headline image
46 Biggest Movers From Yesterday ↗
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares jumped 93.9% to close at $35.36 on Monday. The FDA removed the full clinical hold on Protagonist Therapeutics’... 
Via Benzinga
News headline image
Why Are Ocular Therapeutix Shares Trading Higher Today? ↗
The FDA has approved Ocular Therapeutix Inc's (NASDAQ: OCUL) supplemental application to broaden the Dextenza label. The approval now adds an indication for... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Protagonist Therapeutics (NASDAQ:PTGX) shares increased by 92.43% to $35.1 during Monday's regular session. Trading volume for this security as of 12:30 EST is... 
Via Benzinga
News headline image
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
From Ocular Therapeutix, Inc.
Via Business Wire
News headline image
28 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares surged 85% to $33.78. The FDA removed the full clinical hold on Protagonist Therapeutics’ rusfertide clinical... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates ↗
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
News headline image
Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations
From Ocular Therapeutix, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.